Conferences

Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Epcoritamab as Single Therapy for Relapsed/Refractory CLL/SLL

December 19, 2024

Learn about epcoritamab's clinical trial outcomes for R/R CLL, focusing on response rates, safety improvements, and treatment implications.

A Fixed-Duration Regimen for CLL: Acalabrutinib + Venetoclax Results from the AMPLIFY Trial

December 17, 2024

Discover how the AMPLIFY trial offers promising new fixed-duration treatment options for patients with newly diagnosed CLL.

The Best of ASH 2024

December 10, 2024

Discover the board's selection of best abstracts at the 66th annual ASH conference.

Effects of Eating Fiber, Plant-Based Diet, Keto Diet, and Smoking on Certain Blood Cancers

December 10, 2024

Read research highlights from the ASH 2024 conference how certain lifestyle choices affect blood cancers.

ASH 2024: Research Highlights in CLL/SLL

December 09, 2024

Out of the many publications presented at the ASH 2024 conference for chronic lymphocytic leukemia (CLL), read about some of the session topics from today.

First Day of ASH 2024- Busy Times in Leukemia Research!

December 06, 2024

Discover key updates, research insights, and expert discussions on CLL, AML, and ALL from ASH 2024. Stay tuned for HealthTree's coverage.

What is the ASH Conference?

December 02, 2024

The American Society of Hematology's annual conference is a significant event for the blood cancer community, including those involved in CLL research.

Real-world Results for Preventing Infections in CLL and Non-Hodgkin Lymphoma Patients

November 15, 2024

New study shows IVIG replacement lowers infection risk in CLL and NHL patients, highlighting the need for better IgG testing and IgRT guidelines.

Discussing Unmet Clinical Needs in CLL with Silvia Deaglio, MD, PhD

August 27, 2024

Dr. Deaglio outlines two CLL groups that need special attention from researchers to advance treatment options.

EHA 2024: 4 Years on, Ibrutinib + Venetoclax Keeps High-Risk CLL in Remission

July 22, 2024

Dr. Jacobs shared findings about the outcomes of a fixed-duration treatment combination of ibrutinib and venetoclax for patients with high-risk CLL.

Conferences

Recent Articles

Epcoritamab as Single Therapy for Relapsed/Refractory CLL/SLL